(Avishek Das/Getty Images)

Hims rises on revenue beat, discloses it’s again in partnership talks with Novo

Hims also disclosed on Monday that it’s in talks with Novo Nordisk to make the drugmaker’s weight-loss drugs available on its platform. Last time, that didn’t go so well.

J. Edward Moreno

11/3/25 4:14PM

Hims & Hers reported third-quarter earnings results that missed Wall Street estimates but revenue that blew expectations out of the water. The company also said it’s talking with Novo Nordisk again about a potential deal to distribute its branded weight-loss drugs.

The company reported diluted earnings per share of $0.06, less than the $0.09 analysts polled by FactSet were expecting. Hims also reported $598.9 million in sales, significantly more than the $580.2 million the Street was penciling in.

The company narrowed its full-year revenue guidance to about $2.35 billion from between $2.3 billion and $2.4 billion.

Hims also disclosed on Monday that it’s in talks with Novo to make its branded weight-loss drugs available on the telehealth company’s platform. The two previously had a partnership that ended abruptly in June after Novo accused Hims of “illegal mass compounding and deceptive marketing.”

Hims has been looking for ways to spark sales growth as its core sexual health business slows down and its ability to sell weight-loss treatments remains on shaky ground. In recent months, the company has introduced testosterone treatments and menopause regimens, as well as GLP-1 “micro-dosing” options.

Additionally, the company disclosed that it’s continuing to explore international expansion “in key markets including Brazil, the U.K., Germany, and Australia.” Earlier this year, the company acquired a European peer, Zava, for $265.7 million, and announced plans to expand to Canada in 2026 to offer generic versions of Novo’s weight-loss shot.

Hims said it plans to launch “comprehensive lab testing capabilities in the near future.” That will support its upcoming “longevity” specialty as well as its injectable testosterone offerings, both of which it says are coming next year.

J. Edward Moreno5h

Molina implodes after earnings miss, gloomy guidance

Molina Healthcare tanked after it reported earnings results that missed Wall Street expectations and gave disappointing full-year guidance.

For the last three months of 2025, Molina reported:

An adjusted loss per share of $2.75, compared to the $0.34 earnings per share analysts polled by FactSet were expecting. The company said about $2 per share of its earnings miss was due to “retroactive premium adjustments attributable to the Company’s Medicaid business in California and ongoing medical cost pressure in Medicare and Marketplace.”
Revenue of $11.3 billion, compared to the $10.8 billion the Street was penciling in.
A medical cost ratio of 94.6%, higher than the 93.1% analysts expected.

For the full year in 2026, Molina expects:

Adjusted earnings per share of at least $5.00, compared to the $13.66 analysts had forecast. Molina said its guidance takes into account ongoing losses in its traditional Medicare Advantage Part D business, which it now plans to exit in 2027.
Revenues of about $42.2 billion, compared to the $46.6 billion analysts had penciled in.
Its medical cost ratio to sit at 92.6%, while analysts had expected 91.4%.

Health insurers have been under pressure for the past year amid rising health costs. Molina, one of the largest providers of ACA Marketplace plans, has taken a hit as tax credits for the program lapsed in January.

Molina’s report also dragged down competitors, including Centene, which is also a major provider of ACA plans and reports earnings Friday morning.

Bloom Energy surges after topping expectations for sales, EPS

Here’s how the print looked at first glance.

Matt Phillips5h

Max Knoblauch5h

Roblox surges as it guides for stronger-than-expected full-year bookings, touts AI vision

Kid-centric gaming platform Roblox reported its fourth-quarter results after the market closed on Thursday. Its shares surged more than 20% in after-hours trading.

For the full year ahead, Roblox guided for bookings of between $8.28 billion and $8.55 billion, which would represent annual growth of 22% to 26%. That’s well ahead of Wall Street’s estimates: analysts polled by FactSet expected $8.03 billion.

Roblox forecasts Q1 bookings to land between $1.69 billion and $1.74 billion, compared to the $1.7 billion Wall Street consensus estimate.

An average of 144 million daily users logged on to Roblox in its fourth quarter, beating estimates of 138 million and up 69% from last year. The platform paid out $1.5 billion to creators last year, up from $922 million in 2024.

Roblox engagement surged in 2025, a year marred by several legal issues surrounding child safety on the platform. Late last year, analysts began to warn that some of its most popular titles were past their peak.

Recently, shares of the company have dropped on investor fears of Google’s Project Genie AI tool, which generates playable worlds. As of Thursday’s close, Roblox had shed more than $10 billion in market cap since Project Genie launched. On Wednesday, Roblox appeared to answer Genie’s release with the open beta launch of its own “4D” generative-AI tool. Roblox’s tool lets users generate objects made up of multiple working parts (e.g., a drivable car with spinning wheels) as opposed to static 3D objects.

In its letter to shareholders, Roblox said it was “innovating aggressively in AI to accelerate the creation of content, improve the safety of our platform, and fuel ongoing user engagement, discovery and monetization improvements.”

Jon Keegan

Amazon slides as it misses on Q4 earnings, gives downbeat profit guidance

The tech giant also forecast it would spend $200 billion on capex in 2026.